Despite the clear cut development of symptomatic, BNP-confirmed HF, the unpredictable timing of the onset and deterioration of HF and in ability to achieve a stable time window for interventional tests meant we did not progress with the model for the study of novel therapeutics. This evidence concerns the gene NPPB and hydrops fetalis.